In another approach evaluating the efficacy of anti-PD-1/PD-L1 treatment, the outcome of inhibition of the cystine/glutamate antiporter (xCT) was investigated in mouse model of ICI-treated metastatic melanoma [111]. The gene discussed is CD274; the disease is metastatic melanoma.